Rani Therapeutics Q3 net loss decreases, extends cash runway into 2028

Rani Therapeutics Holdings

06/11/2025 22:39

Overview

Rani announced $1.085 bln collaboration with Chugai Pharmaceutical for oral therapy development

Completed $60.3 mln oversubscribed private placement, extending cash runway into 2028

Net loss for Q3 2025 decreases to $7.9 mln from $12.7 mln in Q3 2024

Outlook

Rani plans to initiate Phase 1 trial for RT-114 by end of 2025

Company expects cash runway to extend into 2028

Result Drivers

OVERSUBSCRIBED PRIVATE PLACEMENT - $60.3 mln private placement led by Samsara BioCapital supports financial stability

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$7.91 mln
Q3 Operating Expenses
$7.26 mln
Q3 Operating Income
-$7.26 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Rani Therapeutics Holdings Inc is $10.50, about 76.2% above its November 5 closing price of $2.50

Press Release: ID:nGNX24whQQ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)